New pyrrolopyridine-based thiazolotriazoles as diabetics inhibitors: enzymatic kinetics and in silico study

Future Med Chem. 2023 Mar;15(5):405-419. doi: 10.4155/fmc-2022-0306. Epub 2023 Apr 4.

Abstract

Aim: To synthesize pyrrolopyridine-based thiazolotriazoles as a novel class of α-amylase and α-glucosidase inhibitors and to determine their enzymatic kinetics. Methodology: Pyrrolopyridine-based thiazolotriazole analogs (1-24) were synthesized and characterized through proton nuclear magnetic resonance, carbon-13 nuclear magnetic resonance and high-resolution electron ionization mass spectrometry. Results: All synthesized analogs displayed good inhibitory potential of α-amylase and α-glucosidase ranging 17.65-70.7 μM and 18.15-71.97 μM, respectively, compared with the reference drug, acarbose (11.98 μM and 12.79 μM). Analog 3 was the most potent among the synthesized analogs, having α-amylase and α-glucosidase inhibitory activity at 17.65 and 18.15 μM, respectively. The structure-activity relationship and binding modes of interactions between selected analogs were confirmed via docking and enzymatic kinetics studies. The compounds (1-24) were tested for cytotoxicity against the 3T3 mouse fibroblast cell line and were observed to be nontoxic.

Keywords: diabetics II inhibitors; enzymatic kinetics study; new pyrrolopyridine-based thiazolotriazole.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus*
  • Glycoside Hydrolase Inhibitors / chemistry
  • Heterocyclic Compounds*
  • Kinetics
  • Mice
  • Molecular Docking Simulation
  • Molecular Structure
  • Structure-Activity Relationship
  • alpha-Amylases
  • alpha-Glucosidases / metabolism

Substances

  • alpha-Glucosidases
  • Glycoside Hydrolase Inhibitors
  • Heterocyclic Compounds
  • alpha-Amylases